Our expertise of Phase I studies is a definite asset for bioequivalence clinical studies.
We consider bioavailability/bioequivalence clinical studies with specific approches. Some studies passed the test of bioequivalence with a number as small as 10 and 12 subjects.

We conducted different BE/BA studies, we have specific experience and expertise with the modified-release products. We permanently ensure the conformity of the study to the applicable lawful standards.